Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TMCI 
Treace Medical Concepts Inc (TMCI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/10/2025: TMCI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.56
1 Year Target Price $6.56
| 2 | Strong Buy |
| 0 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -35.67% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 284.50M USD | Price to earnings Ratio - | 1Y Target Price 6.56 |
Price to earnings Ratio - | 1Y Target Price 6.56 | ||
Volume (30-day avg) 7 | Beta 0.69 | 52 Weeks Range 3.40 - 10.79 | Updated Date 11/10/2025 |
52 Weeks Range 3.40 - 10.79 | Updated Date 11/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.8 |
Earnings Date
Report Date 2025-11-11 | When - | Estimate -0.2755 | Actual -0.2216 |
Profitability
Profit Margin -22.89% | Operating Margin (TTM) -29.23% |
Management Effectiveness
Return on Assets (TTM) -14.77% | Return on Equity (TTM) -51.63% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 396268768 | Price to Sales(TTM) 1.3 |
Enterprise Value 396268768 | Price to Sales(TTM) 1.3 | ||
Enterprise Value to Revenue 1.85 | Enterprise Value to EBITDA -40.95 | Shares Outstanding 63173126 | Shares Floating 47612056 |
Shares Outstanding 63173126 | Shares Floating 47612056 | ||
Percent Insiders 25.39 | Percent Institutions 60.1 |
Upturn AI SWOT
Treace Medical Concepts Inc
Company Overview
History and Background
Treace Medical Concepts Inc. was founded in 2014 and went public in 2021. It focuses on surgical solutions for bunion correction.
Core Business Areas
- Bunion Correction: Develops and commercializes surgical systems for treating bunions and related deformities.
Leadership and Structure
The leadership team is headed by the CEO. The company has a standard corporate structure with departments for R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Lapiplastyu00ae System: A 3D bunion correction procedure. Treace claims a strong market share in the bunion correction market (estimated around 25%), though direct comparative market share data is scarce. Competitors include Stryker, Wright Medical (now part of Stryker), and Johnson & Johnson (DePuy Synthes).
Market Dynamics
Industry Overview
The market for orthopedic surgical devices is large and growing, driven by an aging population and increasing prevalence of foot and ankle deformities.
Positioning
Treace Medical Concepts focuses on the niche market of bunion correction with its Lapiplasty system. Their competitive advantage lies in the technology itself and marketing/sales of this innovative product.
Total Addressable Market (TAM)
The total addressable market for bunion correction is estimated to be in the billions of dollars annually. Treace is well-positioned to capture a significant portion of this market, provided its technology is accepted and adopted.
Upturn SWOT Analysis
Strengths
- Proprietary Lapiplastyu00ae System
- Strong clinical data supporting Lapiplasty
- Dedicated sales force
- Growing market adoption
Weaknesses
- Sole reliance on Lapiplasty system
- Relatively small company size compared to competitors
- High marketing and sales expenses
- Limited product diversification
Opportunities
- Expanding Lapiplasty indications
- Geographic expansion
- Development of new foot and ankle solutions
- Partnerships and acquisitions
Threats
- Competition from established orthopedic companies
- Reimbursement pressures from insurance providers
- Potential product liability claims
- Economic downturn affecting elective surgeries
Competitors and Market Share
Key Competitors
- STRY
- JNJ
Competitive Landscape
Treace's advantage lies in its innovative technology. However, it faces competition from much larger, more established companies with broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Treace has experienced rapid revenue growth since commercializing Lapiplasty.
Future Projections: Analysts project continued revenue growth, driven by increased market penetration and geographic expansion.
Recent Initiatives: Recent initiatives include expanding the sales force, investing in marketing, and pursuing new product development.
Summary
Treace Medical Concepts is a rapidly growing company with a promising technology for bunion correction. Its revenue growth is impressive, but it needs to manage expenses to achieve profitability. The company must continue its marketing efforts and compete against well-established competitors.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Treace Medical Concepts Inc
Exchange NASDAQ | Headquaters Ponte Vedra, FL, United States | ||
IPO Launch date 2021-04-23 | Founder, Chairman & CEO Mr. John T. Treace | ||
Sector Healthcare | Industry Medical Devices | Full time employees 477 | Website https://www.treace.com |
Full time employees 477 | Website https://www.treace.com | ||
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible correction of metatarsus adductus deformities and osteoarthritis of the midfoot. It serves physicians, surgeons, ambulatory surgery centers and hospitals related to the surgical management of bunion and related midfoot deformities. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.